Speciality: Emergency Medicine
Description:
A warm welcome to all the medical professionals in this interesting session on Use of Biologics in IgE mediated diseases A case based discussion on Omalizumab
The use of biologics in treating IgE-mediated diseases has revolutionized the management of conditions like asthma, chronic idiopathic urticaria, and allergic rhinitis. These therapies target specific pathways involved in the allergic response, offering more precise and effective treatment options compared to traditional therapies. Omalizumab, an anti-IgE monoclonal antibody, is a prominent biologic used in these cases.
Omalizumab works by binding to free IgE antibodies in the blood, preventing them from attaching to IgE receptors on mast cells and basophils. This action inhibits the release of inflammatory mediators that cause allergic symptoms. By directly targeting the IgE pathway, omalizumab reduces the frequency and severity of allergic reactions, offering significant relief for patients with severe allergic conditions.
In a case-based discussion, a patient with severe allergic asthma who has not responded to standard treatments can illustrate the effectiveness of omalizumab. After initiating omalizumab therapy, the patient experiences a marked reduction in asthma exacerbations and improved lung function.
Therefore, get an overall knowledge of use of biologics in IgE mediated diseases A case based discussion on Omalizumab
See More Webinars @ Hidoc Webinars
1.
Admissions, medical schools, costs, and eligibility requirements information for FNB Onco-Anesthesia.
2.
A small rise in cancer was observed following the 1986 Chernobyl accident.
3.
A researcher has found that yoga exhibits the "most improvement" in helping long-term cancer survivors restore their brain health.
4.
The hidden costs of cancer for young survivors are derailing their financial futures
5.
Report reveals lung cancer is the leading cause of cancer deaths in Florida
1.
Pediatric Oncology at the Cutting Edge: From Early Diagnosis to Lifesaving Therapies
2.
Insights into Doxorubicin and Liposomal Doxorubicin in Extra-Abdominal Desmoid-Type Fibromatosis
3.
Unlocking the Secrets of Ringed Sideroblasts: A New Frontier in Hematology
4.
Methemoglobinemia in OR & ICU: Pathophysiology, Detection, and Management Review
5.
What You Need To Know About Secondary Polycythemia: Treatment & Symptoms
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Navigating the Brain Barrier: The CNS Challenge in ALK+ NSCLC
2.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part IV
3.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma
4.
Understanding the causes of anemia in adults beyond nutritional deficiencies
5.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part III
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation